ERBB2 and breast carcinoma: Here, we report that an optimised protocol for flow cytometric analysis enables the quantitative detection of single HER2+EVs and quantifies the expression levels of on these EVs released from breast cancer cells in vitro as well as on EVs circulating in the plasma of patients with breast cancer.